Ontak + CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Nov 1, 2005 → Jan 1, 2008
NCT ID
NCT00337987About Ontak + CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Ontak + CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy is a phase 2 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00337987. Target conditions include Peripheral T-Cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00337987 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma